| (Values in U.S. Thousands) | Mar, 2018 | Dec, 2017 | Sep, 2017 | Jun, 2017 | Mar, 2017 |
| Sales | 1,610 | 1,470 | 2,050 | 1,110 | 420 |
| Sales Growth | +9.52% | -28.29% | +84.68% | +164.29% | -57.58% |
| Net Income | 630 | -220 | -680 | 740 | -1,040 |
| Net Income Growth | +386.36% | +67.65% | -191.89% | +171.15% | -67.74% |
Immudyne Inc (IMMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ImmuDyne, Inc. develops, manufactures and sells immune support products. The Company's core nutraceutical and cosmetic product lines consist of yeast beta glucans in oral and topical applications. ImmuDyne, Inc. is based in Mount Kisco, New York.